Immatics
NEWS
The two companies struck a strategic collaboration and option agreement to harness the power of Immatics’ T-Cell Receptor Engineered T-cell Therapy programs and aim them at solid tumors.
Immatics Biotechnologies GmbH announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer.
Denmark-based Genmab A/S struck a discovery and development deal with Immatics Biotechnologies GmbH.
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
JOBS
IN THE PRESS